Off-label uses of biologics in dermatology: Rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (Part 2 of 2)

Authors:
  • KNKara Nunley
    Kara Nunley
  • MHMichael P. Heffernan
    Michael P. Heffernan

Abstract
No abstract available

This publication has 265 references indexed in Scilit: